Top

Annals of Surgical Oncology

Published in:

01-09-2007 | Educational Review

Role of Lymphadenectomy in Surgical Treatment of Solid Tumors: An Update on the Clinical Data

Authors: James E. Gervasoni Jr., PhD, MD, FACS, Samer Sbayi, MD, Blake Cady, MD, FACS

Published in: Annals of Surgical Oncology | Issue 9/2007

Abstract

Background

The role of lymphadenectomy as an adjunct of standard excision for treatment of cancer is highly debated and controversial. Standard practice for treatment of solid tumors is resection with regional lymphadenectomy. This surgical concept assumes that cancers grow and spread in an orderly manner, from primary cancer to regional lymph nodes and finally to vital organs. We reviewed randomized trials, published a description of lymphatic anatomy and physiology, and presented data that disputed the role of lymphadenectomy as standard practice. The present review updates the literature and reiterates the concept that lymphadenectomy does not increase survival in the surgical treatment of solid tumors.

Methods

We reviewed the English-language literature (Medline) for prospective randomized trials and nonrandomized reports, as well as retrospective studies addressing the role of lymphadenectomy in cancers of the esophagus, lung, stomach, pancreas, breast, and skin (melanoma) reported between 2000 and 2006.

Results

This extensive review demonstrates that there are few prospective randomized trials assessing patient survival with solid tumors that contrast resection with or without lymphadenectomy. However, there was at least one, and for some cancers more than one, prospective randomized trial for each organ site studied, and the data demonstrate no statistically significant difference in overall survival of patients treated with or without lymphadenectomy. Most nonrandomized and retrospective studies, with a few exceptions, support the conclusions of randomized trials; lymphadenectomy does not improve overall survival in solid tumors. Overall survival is primarily a function of the biological nature of the primary tumor, as evidenced by lymphovascular invasion, lymph node involvement, and other prognostic features.

Conclusions

This extensive literature review of recent reports indicates that lymphadenectomy does not improve overall survival. Lymph node resection should be conceived in terms of staging, prognosis, and regional control only.

Gervasoni JE Jr, Taneja C, Chung MA, Cady B. Biologic and clinical significance of lymphadenectomy. Surg Clin North Am 2000;80:1631–73PubMed

Moynihan BGA. The surgical treatment of cancer of the sigmoid flexure and rectum. Surg Gynecol Obstet 1908;6:463–6

Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907;46:1–19PubMedCrossRef

Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatial resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662–9PubMed

Tsurumaru M, Kajiyama Y, Udagawa H, Akiyama H. Outcome of extended lymph node dissection for squamous cell carcinoma of the thoracic esophagus. Ann Thorac Cardiovasc Surg 2001;7:325–9PubMed

Tachibana M, Kinugasa S, Yoshimura H, et al. Extended esophagectomy with 3-field lymph node dissection for esophageal cancer. Arch Surg 2003;103:1383–90

Fujita H, Sueyoshi S, Tanaka T, et al. Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy. World J Surg 2003;27:571–9PubMed

Igaki H, Tachimori Y, Kato H. Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection. Ann Surg 2004;239:483–90PubMed

Tachibana M, Kinugasa S, Yoshimura H, et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg 2005;189:98–109PubMed

10.

Tabira Y, Okuma T, Sakaguchi T, et al. Three-field dissection or two field dissection? A proposal of new algorithm for lymphadenectomy. Hepatogastroenterology 2005;51:1015–20

11.

Nakagawa S, Kanda T, Kosugi S, et al. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 2004;198:205–11PubMed

12.

Komatsu S, Shioaki Y, Ichikawa D, et al. Survival and clinical evaluation of salvage operation for cervical lymph node recurrence in esophageal cancer. Hepatogastroenterology 2005;52:796–9PubMed

13.

Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002;236:177–83PubMed

14.

Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R₀resections: impact on staging, disease-free survival, and outcome. A plea for adaptation of TNM classification in Upper-half esophageal carcinoma. Ann Surg 2004;240:962–74PubMed

15.

D’Journo XB, Doddoli C, Michelet P, et al. Transthoracic esophagectomy for adenocarcinoma of the oesophagus: standard versus extended two-field mediastinal lymphadenectomy? Eur J Cardiothoracic Surg 2005;27:697–704

16.

Siewert JR, Stein HJ, Feith M, et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at single center in the western world. Ann Surg 2001;234:360–9PubMed

17.

Brucher BLDM, Stein HJ, Werner M, Siewert JR. Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer 2001;92:2228–33PubMed

18.

Hosch SB, Stoecklein NH, Pichlmeier U, et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 2001;19:1970–5PubMed

19.

Mueller JD, Stein HJ, Oyang T. Frequency and clinical impact of lymph node micrometastasis and tumor cell microinvolvement in patients with adenocarcinoma of the esophagogastric junction. Cancer 2000;89:1874–82PubMed

20.

Waterman TA, Hagen JA, Peters JH. The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma. Ann Thorac Surg 2004;78:1161–9PubMed

21.

Heeren PAM, Kelder W, Blondeel I. Prognostic value of nodal micrometastases in patients with cancer of the gastro-oesophageal junction. Eur J Surg Oncol 2005;31:270–6PubMed

22.

von Rahden BHA, Stein HJ, Feith M, et al. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinoma of the esophagogastric junction. J Clin Oncol 2005;23:874–9

23.

Stein HJ, Feith M, Bruecher BLDM, et al. Early esophageal cancer. Pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005;242:566–75PubMed

24.

Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002

25.

Pera M, Trastek VF, Carpenter HA, et al. Barrett’s esophagus with high-grade dysplasia: an indication for esophagectomy? Ann Thorac Surg 1992;54:1999–2004CrossRef

26.

Headrick JR, Nichols FC III, Miller DL, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002;73:1697–702PubMed

27.

Reed CE. Surgical management of esophageal. Oncologist 1999;4:95–105PubMed

28.

Wu Y, Wang S, Huang Z. Extent of lymphadenectomy in stage I–IIIA non–small cell lung cancer: a randomized clinical trial. Zhonghua Zhong Liu Za Zhi 2001;23:43–5PubMed

29.

Izbicki JR, Passlick B, Pantel K, et al. Effectiveness of radial systematic mediastinal lymphadenectomy in patients with resectable non–small cell lung cancer-results of a prospective randomized study. Ann Surg 1998;227:138–44PubMed

30.

Sugi K, Nawata K, Fujita N, et al. Systematic lymph node dissection for clinically diagnosed peripheral non–small cell cancer less than 2cm in diameter. World J Surg 1998;22:290–5PubMed

31.

Keller SM, Adak S, Wagner H, et al. Mediastinal lymph node dissection improves survival in patients with Stage II and Stage IIIa non–small cell lung cancer. Ann Thorac Surg 2000;70:358–66PubMed

32.

Doddoli C, Aragon A, Barlesi F, et al. Does the extent of lymph node dissection influence outcome in patients with stage I non–small cell lung cancer? Eur J Cardiothorac Surg 2005;27:680–5PubMed

33.

Lardinois D, Suter H, Hakki H, et al. Morbidity, survival, and site of recurrence after mediastinal lymph node dissection versus systematic sampling after complete resection for non–small cell lung cancer. Ann Thorac Surg 2005;80:268–75PubMed

34.

Passlick B, Kubuschock B, Sienel W, et al. Mediastinal lymphadenectomy in non–small cell lung cancer: effectiveness in patients with or without nodal micrometastasis-results of a preliminary study. Eur J Cardiothorac Surg 2002;21:520–6PubMed

35.

Osaki T, Oyama T, Gu Chun–Dong, et al. Prognostic impact of micrometastatic tumor cells in the lymph node and bone marrow of patients with completely resected stage I non–small cell lung cancer. J Clin Oncol 2002;20:2930–6

36.

Gajra A, Newman N, Gamble GP, et al. Effect of number of lymph nodes sampled on outcome in patients with stage I non–small cell lung cancer. J Clin Oncol 2003;21:1029–34PubMed

37.

Sigurdson ER. Lymph node dissection: is it diagnostic or therapeutic. J Clin Oncol 2003;21:965–7PubMed

38.

Allen MS. Mediastinal lymph node dissection for non–small cell lung cancer. J Thorac Cardiovasc Surg 2005;130:241–2PubMed

39.

Hartgrink HH, van de Velde CJH, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 2004;22:2069–77PubMed

40.

Degiuli M, Sasako M, Calgaro M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group randomized surgical trial. Eur J Surg Oncol 2004;30:303–8PubMed

41.

Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy. Japan Clinical Oncology Group Study 9501. J Clin Oncol 2004;22:2767–73PubMed

42.

McCulloch P, Nita ME, Kazi H, Gama-Rodrigues JJ. Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br J Surg 2005;92:5–13PubMed

43.

Hyung WJ, Lee JH, Choi SH, et al. Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol 2002;9:562–7PubMedCrossRef

44.

Kooby DA, Suriawinata A, Klimstra DS, et al. Biologic predictors of survival in node-negative gastric cancer. Ann Surg 2003;237:828–37PubMed

45.

Dicken BJ, Saunders LD, Jhangri GS, et al. Gastric cancer: establishing predictors of biologic behavior with use of population-based data. Ann Surg Oncol 2004;11:629–35PubMed

46.

Dicken BJ, Graham K, Hamilton SM, et al. Lymphovascular invasion is associated with poor survival in gastric cancer. An application of gene-expression and tissue array techniques. Ann Surg 2006;243:64–73PubMed

47.

Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of US gastric carcinoma patients treated with gastrectomy: sixth edition American Joint Committee on Cancer Staging, Proximal Disease, and the “Different Disease” Hypothesis. Cancer 2000;88:921–32PubMed

48.

Petrelli NJ. The debate is over; it’s time to move on. J Clin Oncol 2004;22:2041–2PubMed

49.

Lee WJ. It is still not the time to change surgical strategy for gastric cancer (letter to the editor). Ann Surg Oncol 2005;12:194–5PubMed

50.

Pedrazzoli S, Di Carlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of Adenocarcinoma of the head of the pancreas. A multicenter prospective randomized study. Ann Surg 1998;228:508–17PubMed

51.

Nimura Y, Nagino M, Kato H, et al. Regional versus extended lymph node dissection in radical pancreaticoduodenectomy for pancreatic cancer: a multicenter randomized controlled trial. HPB Surg 2004;6(Suppl 1):2

52.

Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreaticoduodenectomy with pancreaticoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618–30PubMed

53.

Riall TS, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarinoma—part 3: update on 5-year survival. J Gastrointest Surg 2005;9:1191–206PubMed

54.

Pedrazzoli S, Pasquali C, Sperti C. Extent of lymphadenectomy in the resection of pancreatic cancer. Analysis of the existing evidence. Rocz Akad Med Bialymst 2005;50:85–90PubMed

55.

Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420–30PubMed

56.

Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986;61:697–705PubMed

57.

Balch CM, Soong S-J, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255–66PubMed

58.

Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial. Lancet 1998;351:793–6PubMed

59.

Thomas JM. Caution with sentinel node biopsy in cutaneous melanoma. Br J Surg 2006;93:129–30PubMed

60.

Reintgen D, Pendas S, Jakub J, et al. National trials involving lymphatic mapping for melanoma: the Multicenter Selection Lymphadenectomy Trial, the Sunbelt Melanoma Trial, and the Florida Melanoma Trial. Semin Oncol 2004;31:363–73PubMed

61.

Morton DL, Thompson JF, Cochran AH, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307–71PubMed

62.

Thomas JM, Clark MA. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol 2004;30:686–91PubMed

63.

Estourgie SH, Nieweg OE, Kroon BBR. High incidence on in-transit metastases after sentinel node biopsy in patients with melanoma. Br J Surg 2004;91:1370–1PubMed

64.

Kretschmer L, Beckmann I, Thoms KM, et al. Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas. Eur J Cancer 2005;41:531–8PubMed

65.

van Poll D, Thompson JF, Colman MH, et al. A sentinel node biopsy does not increase the incidence on in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol 2005;12:597–608PubMed

66.

Kang JC, Wanek LA, Essner R, et al. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol 2005;23:4764–70PubMed

67.

Pawlik TM, Ross MI, Johnson MM. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005;12:587–96PubMed

68.

Takeuchi H, Morton DJ, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph node in melanoma patients. J Clin Oncol 2004;22:2671–80PubMed

69.

Essner R. Sentinel lymph node biopsy and melanoma biology. Clin Cancer Res 2006;12(7 Suppl):2320s–5sPubMed

70.

Gervasoni JE Jr, Taneja C, Chung MA, Cady B. Axillary dissection in the context of the biology of lymph node metastases. Am J Surg 2000;180:278–83PubMed

71.

Fisher B. The surgical dilemma in the primary therapy of invasive breast cancer: a critical appraisal. Curr Probl Surg 1970;October:3–53

72.

Fisher B. Laboratory and clinical research in breast cancer—a personal adventure: the David A. Karnofsky Memorial Lecture. Cancer Res 1980;40:3863–74PubMed

73.

Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347:567–75PubMed

74.

Zurrida S, Orecchia R, Galimberti V, et al. Axillary radiotherapy instead of axillary dissection: a randomized trial. Italian Oncological Senology Group. Ann Surg Oncol 2002;9:117–9

75.

Veronesi U, Orecchia R, Zurrida S, et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol 2005;16:383–8PubMed

76.

Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol 2004;22:97–101PubMed

77.

Martelli G, Boracchi P, De Palo M, et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer. Results after 5 years of follow-up. Ann Surg 2005;242:1–6PubMed

78.

Cady B. A randomized trial comparing axillary dissection to no axillary dissection in elderly patients with T1N0 breast cancer. Results after long-term follow-up (editorial). Ann Surg 2005;242:7–9

79.

Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection. A follow-up study of 4008 procedures. Ann Surg 2004;240:462–71PubMed

80.

Breast cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2003;1:148–88

81.

Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection I breast cancer. N Engl J Med 2003;349:546–53PubMed

82.

Langer I, Marti WR, Guller U, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 2005;241:152–8PubMed

83.

Zavagno G, Carcoforo P, Franchini Z, et al. Axillary recurrence after negative sentinel lymph node biopsy without axillary dissection: a study on 479 breast cancer patients. Eur J Surg Oncol 2005;31:715–20PubMed

84.

Swenson KK, Mahipal A, Nissen MJ, et al. Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma. Cancer 2005;104:1834–9PubMed

85.

Palesty JA, Foster JM, Hurd TC, et al. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. J Surg Oncol 2006;93:129–32PubMed

86.

Khakpour N, Hunt KK, Kuerer HM, et al. Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. Am J Surg 2005;190:598–601PubMed

87.

Schulze T, Mucke J, Markwardt J, et al. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol 2006;93:109–19PubMed

88.

Kim T, Giulano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006;106:4–16PubMed

89.

Cox C, White L, Allred N, et al. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Ann Surg Oncol 2006;13:708–11PubMed

90.

Guenther JM, Hansen NM, DiFronzo LA, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg 2003;138:52–6PubMedCrossRef

91.

Jeruss JS, Winchester DJ, Sener SF, et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol 2005;12:34–40PubMed

92.

Singletary SE. Early-stage invasive breast cancer: isolated tumor cells in axillary lymph nodes, peripheral blood, and bone marrow. Gen Surg News 2006;33:17–20

93.

Cox C, Vrcel V, Riker A, et al. Significance of sentinel lymph node micrometastasis on survival for patients with invasive breast cancer (abstract 21). Breast Cancer Res Treat 2005;94(Suppl 1):S12–3

94.

International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancer. Lancet 1990;335:1565–8

95.

Cote RJ, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph nodes metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999;354:896–900PubMed

96.

Quan ML, Cody HS. Missed micrometastatic disease in breast cancer. Semin Oncol 2004;31:311–7PubMed

97.

Viale G, Maiorano E, Pruneri G, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg 2005;241:319–25PubMed

98.

Menes TS, Tartter PI, Mizrachi H, et al. Breast cancer patients with pN0(i+) and pN1(mi) sentinel nodes have high rate of nonsentinel node metastases. J Am Coll Surg 2005;200:323–7PubMed

99.

Houvenaeghel G, Nos C, Mignotte H, et al. Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement. Groupe des Chirurgiens de la Federation des Centers de Lutte Center le Cancer. J Clin Oncol 2006;24:1814–22PubMed

100.

Bear H. Sentinel node micrometastases and non-sentinel nodes in breast cancer: how much do we need to know? J Clin Oncol 2006;24:1788–90PubMed

101.

Cserni G, Gregori D, Merletti F, et al. Meta-analysis associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004;91:1245–52PubMed

102.

Julian TB, Krag D, Brown A, et al. Continued technical results of NSABP B-32: does a positive sentinel node biopsy require an axillary dissection? (abstract 20). Breast Cancer Res Treat 2005;94(Suppl 1):S12

103.

Schaapveld M, de Vries EGE, van der Graaf WTA, et al. The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: stage migration or age association? Ann Surg Oncol 2006;13:465–74PubMed

104.

Anderson BO How many nodes are enough? The breast surgeon’s dilemma (editorial). Ann Surg Oncol 2006;13:439–41PubMed

105.

Wilke LG, Giuliano A. Sentinel lymph node biopsy in patients with early-stage breast cancer: status of the National Clinical Trials. Surg Clin North Am 2003;83:901–10PubMed

106.

El-Tamer M, Chun J, Gill M, et al. Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ. Ann Surg Oncol 2005;3:254–9

107.

Lara J, Young S, Velilla R, et al. The relevance of occult axillary micrometastasis in ductal carcinoma in situ. A clinicopathologic study with long-term follow-up. Cancer 2003;98:2105–12PubMed

108.

Broekhuizen LN, Wijsman JH, Peterse JL, et al. The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. Eur J Surg Oncol 2006;32:502–6PubMed

109.

Mabry H, Giuliano AE, Silverstein MJ. What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ? Am J Surg 2006;192:455–7PubMed

110.

Fidler I. The pathogenesis of cancer metastasis: the “seed and soil” hypothesis revisited. Nat Rev 2003;3:1–6CrossRef

111.

Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314–21PubMed

112.

Akekawatchai C, Holland JD, Kochetkova M, et al. Transactivation of CXCR4 by the insulin-like growth factor-1–receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. J Biol Chem 2005;280:39701–8PubMed

Title: Role of Lymphadenectomy in Surgical Treatment of Solid Tumors: An Update on the Clinical Data
Authors: James E. Gervasoni Jr., PhD, MD, FACS
Samer Sbayi, MD
Blake Cady, MD, FACS
Publication date: 01-09-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 9/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9360-5

At a glance: The STEP trials

Springer Medicine

Role of Lymphadenectomy in Surgical Treatment of Solid Tumors: An Update on the Clinical Data

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2007

Heterogenic Loss of BRCA in Breast Cancer: The “Two-Hit” Hypothesis Takes a Hit

Can Completion Lymph Node Dissection Be Avoided for a Positive Sentinel Node in Melanoma?

pN3M0 Gastric Cancer: the Category that Allows the Sub-Classification of Stage-IV Gastric Cancer (IVa and IVb)

An Analysis of Resection vs Transplantation for Early Hepatocellular Carcinoma: Defining the Optimal Therapy at a Single Institution

Atypical Ductal Hyperplasia: Improved Accuracy with the 11-Gauge Vacuum-Assisted versus the 14-Gauge Core Biopsy Needle

Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis